ASP2998

PreclinicalSmall molecule

ASP2998 is one of 5 small molecule programs targeting Locally Advanced or Metastatic Malignant Solid Tumors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced or Metastatic Malignant Solid TumorsRecruiting

Locally Advanced or Metastatic Malignant Solid TumorsPreclinical

Recruiting

Competition

Competitive Landscape

4 competitors in Locally Advanced or Metastatic Malignant Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

2 2

Padcev

Pfizer

Phase 2

2 3

Ayvakit

BBlueprint Medicines

Phase 2

1 4

Paraplatin

AAvyxa

Preclinical

1 5

ASP2998

Astellas

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Locally Advanced or Metastatic Malignant Solid Tumors

NCT07287995

Clinical

Trials by Indication[1]

Locally Advanced or Metastatic Malignant Solid Tumors1 trial

A Phase 1b/2 Study of ASP2998 as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting· Astellas logo

Astellas·Preclinical·NCT07287995·428 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ASP2998. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASP2998 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASP2998. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Astellas

ASP2998

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Locally Advanced or Metastatic Malignant Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News